Loading stock…

Collegium Pharmaceutical, Inc. (COLL) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Collegium Pharmaceutical, Inc.

COLLMarket cap $0.71BPrice $21.9

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and sells non-opioid pain management therapies, including abuse-deterrent opioid formulations designed to curb misuse. It's one of the few pharma companies turning the opioid crisis into a responsible-treatment business model.

In Bastion Portfolios?

52W Return-35%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+19%9

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+4%3

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+352%10

EPS Growth Y+2-7%3

EPS Growth Y+3-13%3

Quality

Margins

EBIT Margin21%8

Net Income Margin6%4

Free Cash Flow Margin41%10

Debt

Net Debt/EBITDA2.63

Efficiency

ROE18%7

ROA3%4

Earnings Stability55

GEAR+STRONG70

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)310

P/E Ratio (Forward 3y)310

P/BV2.36

EV Multiples

EV/EBITDA Fwd410

EV/EBIT Fwd410

Yield

Free Cash Flow Yield46.0%10

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return-39%1

YTD return-53%1

Mid term

Price vs 52wHigh43%1

1 year return-34%2

Long term

3 year return-7%2

5 year return+8%4

Risk Shield

Price Risk

Beta0.48

Volatility44%4

Free Cash Flow

Free Cash Flow Margin41%10

Free Cash Flow Yield46.0%10

Quality

ROCE13%7

Earnings Stability55

Net Debt/EBITDA2.63

02Growth

Is it actually growing, and how fast?

COLLCollegium Pharmaceutical

Revenue FY25$781M

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+352%10

EPS growth, FY27E-7%3

EPS growth, FY28E-13%3

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 19%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about -7%/yr vs revenue 4%/yr).

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK6 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-39%1

YTD return-53%1

MID & LONG-TERM▾SCORE

% of 52-week high43%1

1-year return-34%2

3-year return-7%2

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.1% over three years and +8.1% over five), behind 70% of the market.

It's down 34% over the past year, now 57% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-39%) and so far this year (-53%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Collegium Pharmaceutical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

COLLCollegium Pharmaceutical

Revenue FY25$781M

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+19%9

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+352%10

EPS growth, FY27E-7%3

EPS growth, FY28E-13%3

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 19%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 19%/yr over the last 3 years; forecasts see it cooling to 4%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Earnings are set to fall even as revenue grows (EPS about -7%/yr vs revenue 4%/yr).

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: earnings are forecast to fall.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK6 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-39%1

YTD return-53%1

MID & LONG-TERM▾SCORE

% of 52-week high43%1

1-year return-34%2

3-year return-7%2

5-year return+8%4

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-6%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-7.1% over three years and +8.1% over five), behind 70% of the market.

It's down 34% over the past year, now 57% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-39%) and so far this year (-53%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Collegium Pharmaceutical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community